| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 1,153.88 | 1,176.76 | -1.94 | ||
| Gross Profit (Loss) | 382.45 | 433.14 | -11.7 | ||
| Operational Profit (Loss) | 365.63 | 342.57 | 6.73 | ||
| Net profit (Loss) | 338.8 | 303.33 | 11.69 | ||
| Total Comprehensive Income | 340.33 | 302.36 | 12.56 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 1,961.25 | 1,844.92 | 6.3 | ||
| Profit (Loss) per Share | 2.12 | 1.9 | |||
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | – | – | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year | Revenues decreased during 2024 by 1.9% compared to the previous year, with revenues reaching 1,153.88 million Saudi Riyals compared to 1,176.76 million Saudi Riyals in 2023. This decrease is due to two main factors:
1 )A decrease in sales from the Ministry of Health. 2) A decrease in pharmaceutical sales from subsidiary company. |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | Net profit achieved remarkable growth during 2024, with a 11.7% increase to reach 338.8 million Saudi Riyals, compared to 303.33 million Saudi Riyals in 2023. This increase was accompanied by an improvement in the net profit margin, rising from 25.8% in 2023 to 29.4% in 2024. This growth in net profit is attributed to the following main factors:
1) Exceptional Gains: The company realized non-recurring gains of 55.27 million Saudi Riyals from the sale of a vacant land plot in Al Rayan district of Riyadh during the second quarter of 2024.
2) Decrease in Selling and Marketing Expenses: Selling and marketing expenses decreased from 9.26 million Saudi Riyals in 2023 to 4.19 million Saudi Riyals in 2024. This is due to lower sales from the subsidiary company.
3) Growth in Financing Income: Financing income, which amounted to 6.14 million Saudi Riyals during 2024, reflecting an increase in the company’s cash balance during the year and improved collection efficiency.
4) Increase in Share of Profits from the Associate Company: The share of profits from the associate company increased to 6.72 million Saudi Riyals, compared to 4.18 million Saudi Riyals in the previous year.
5) Decrease in Zakat Expense: The Zakat expense for 2024 decreased to 15.88 million Saudi Riyals, compared to 17.62 million Saudi Riyals for 2023. This is due to a decrease in the estimated Zakat base for the current year. |
| Statement of the type of external auditor’s report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | None |
| Reclassification of Comparison Items | As disclosed in note (38) of the consolidated financial statements for the year ended December 31, 2024, certain comparative figures have been reclassified to conform to the current period’s presentation, to enhance comparability, and to be more relevant to users of the consolidated financial statements. |
| Additional Information | – |
